クローン病患者におけるSAR442970の有効性と安全性を調査する研究

基本情報

NCT ID

NCT06958536

ステータス

募集中

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

99

治験依頼者名

Sanofi

概要

This is a phase 2b, randomized, double-blind, 3-arm study for the treatment of Crohn's disease. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Crohn's disease. The total study duration is up to 168 weeks, with a treatment period of up to 158 weeks including an open-label (OL) long-term extension (LTE) period of up to 104 weeks for eligible participants.

対象疾患

介入

依頼者（Sponsor）